These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29958626)

  • 21. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
    Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer].
    Kashiwagi S; Ishihara S; Asano Y; Kurata K; Tauchi Y; Tokumoto M; Morisaki T; Noda S; Kawajiri H; Takashima T; Onoda N; Hirakawa K
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1951-3. PubMed ID: 25731386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
    Prescrire Int; 2012 Feb; 21(124):37-8. PubMed ID: 22413716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
    Mougalian SS; Feinberg BA; Wang E; Alexis K; Chatterjee D; Knoth RL; Nero D; Miller T; Liassou D; Kish JK
    Future Oncol; 2019 Dec; 15(34):3935-3944. PubMed ID: 31660764
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy.
    Benbow SJ; Cook BM; Reifert J; Wozniak KM; Slusher BS; Littlefield BA; Wilson L; Jordan MA; Feinstein SC
    Neurotox Res; 2016 Feb; 29(2):299-313. PubMed ID: 26659667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study].
    Sasaki T; Oshima Y; Mishima E; Ban A; Katsuragawa K; Nagamatsu H; Yoshioka Y; Tsukiyama I; Hisada T; Itakura Y; Mizutani M
    Yakugaku Zasshi; 2016 Jul; 136(7):1023-9. PubMed ID: 27040459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
    Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
    Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience].
    Hattori M; Fujita T; Sawaki M; Kondo N; Horio A; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):737-41. PubMed ID: 23863649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
    Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of eribulin for metastatic breast cancer patients].
    Okishiro M; Egawa C; Kusama H; Matsushita K; Hashimoto N; Kawashima H; Mukai Y; Hamanaka M; Takeno A; Sakisaka H; Nakahira S; Taniguchi H; Suzuki R; Takeda Y; Kato T; Tamura S; Takatsuka Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):215-9. PubMed ID: 24743200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
    Tanni KA; Truong CB; Johnson BS; Qian J
    Crit Rev Oncol Hematol; 2021 Jul; 163():103375. PubMed ID: 34087344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
    Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.